Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Vox Sang ; 109(1): 91-4, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25833739

ABSTRACT

Platelets are prophylactically transfused to patients receiving myeloablative chemotherapy. The trigger can be adapted if a patient has risk factors for bleeding. We performed an international survey to quantify differences in transfusion policies. While platelet counts are most important, bleeding, fever, use of anticoagulants and invasive procedures also determine transfusion strategies. The largest variation of triggers was observed for lumbar punctures and removal of central venous catheters.


Subject(s)
Platelet Transfusion/adverse effects , Adult , Aged , Anticoagulants/therapeutic use , Fever/etiology , Guidelines as Topic , Hematologic Neoplasms/pathology , Hemorrhage/prevention & control , Humans , Middle Aged , Platelet Count , Risk Factors , Surveys and Questionnaires , Thrombocytopenia/prevention & control
2.
Transfus Med ; 22(6): 426-31, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23036067

ABSTRACT

BACKGROUND: The reported percentage of haemato-oncological patients experiencing bleeding complications is highly variable, ranging from 5 to 70%, posing a major problem for comparison of clinical platelet transfusion trials using bleeding complications as a primary endpoint. In a pilot study we assessed the impact of the design of scoring of bleeding on the percentage of patients with WHO grade 2 or higher bleeding grades. STUDY DESIGN AND METHODS: We performed a prospective, observational study using a rigorous bleeding observation system in thrombocytopenic patients with haemato-oncological disorders. Endpoints of the study were the percentage of patients and days with bleeding WHO grade ≥ 2 comparing designs in which skin bleeding represent a continuation of a previous bleed or a new bleed. RESULTS: In four participating hospitals 64 patients suffering 870 evaluable thrombocytopenic days (platelet count < 80 × 10(9) L(-1)) were included. At least one episode of bleeding grade ≥ 2 occurred in 36 patients (56%). Most grade 2 bleeding complications occurred mucocutaneously. The percentage of days with bleeding of grade ≥ 2 was 16% but decreases to 8% when only newly developed skin bleeding was included. CONCLUSION: Rigorous daily observation results in a bleeding incidence that is comparable to recent reportings applying the same method. The results of this study show that censoring for stable skin bleeding has a profound effect on bleeding incidence per day. The clinical relevance of rigorous or clinically judged bleeding scores as an endpoint remains to be defined.


Subject(s)
Hematologic Neoplasms , Hemorrhage , Platelet Transfusion , Adult , Aged , Female , Hematologic Neoplasms/blood , Hematologic Neoplasms/complications , Hematologic Neoplasms/epidemiology , Hematologic Neoplasms/therapy , Hemorrhage/blood , Hemorrhage/epidemiology , Hemorrhage/etiology , Hemorrhage/therapy , Humans , Incidence , Male , Middle Aged , Platelet Count , Prospective Studies , Thrombocytopenia/blood , Thrombocytopenia/epidemiology , Thrombocytopenia/etiology , Thrombocytopenia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...